ClinicalTrials.gg
Active, not recruitingNCT07143604GAMBITUpdated Sep 30, 2026

A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2

A Phase 2 interventional study of AZD0901 in Gastric Cancer and Gastroesophageal Junction Cancer, sponsored by AstraZeneca. Active, not recruiting at 13 sites in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Updated Sep 30, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Stomach Neoplasms by AstraZeneca — 10 open to participants now, 18 under way, 3 of them phase 3. Stomach Neoplasms · AstraZeneca.

Enrollment
21st of 27
33 · median 124
Started
2025
with 4 others
Phase 2
9 of 30
4 open now
Primary completion
2026-08
later than 3 of 17 live
Registered
27th of 30
by date

Among the 30 studies in Stomach Neoplasms by AstraZeneca, this one is the 21st largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2025, is one of 9 in phase 2, reaches primary completion later than 3 of the 17 other live ones, and was the 27th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

10 of the 30 studies in Stomach Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Stomach Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to measure the efficacy and safety of AZD0901 monotherapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.

Read the detailed description

This is a Phase II, single arm, open label, multicentre study, assessing the efficacy and safety of AZD0901 in participants with advanced/metastatic gastric or gastroesophageal junction adenocarcinoma expressing Claudin18.2. The results of the study will provide clinical data on efficacy and safety of an innovation drug in Russian Federation.

03

Conditions studied

  • Gastric Cancer
  • Gastroesophageal Junction Cancer

Browse trials for

Keywords

  • Gastric cancer
  • Gastroesophageal junction cancer
  • Claudin 18.2
  • AZD0901
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed unresectable, locally advanced or adenocarcinoma of gastric, GEJ, or distal esophagus, with positive CLDN18.2 expression.
  • Disease progression on or after at least one prior regimen for advanced or metastatic disease, which included a fluoropyrimidine and a platinum, for advanced or metastatic disease.
  • Must have at least one assessed by the Investigator based on 1.1.
  • performance status of 0 or 1.
  • Minimum of ≥12 weeks.
  • Adequate organ and bone marrow function.
  • Minimum body weight of 40 kg.
  • Sex and Requirements.

Exclusion criteria

Exclusion Criteria:

  • Participants with known positive status as defined as IHC 3+ or IHC 2+/ISH +.
  • Participant has significant or unstable gastric bleeding and/or untreated gastric ulcers.
  • or CNS pathology.
  • Participant has known corneal disease (eg, active keratitis or corneal ulcerations).
  • Persistent toxicities ( Grade ≥2) caused by previous anticancer therapy.
  • History of thromboembolic events.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    AZD0901

    Participants will receive AZD0901 IV, Q3W

    Drug: AZD0901

Interventions

  • Participants will receive AZD0901 IV, Q3W

    Also known as: Sonesitatug Vedotin

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, as determined by the investigator per RECIST 1.1 to all dosed participants

    Time frame: At month 6 after date of first dose

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as time from date of first dose until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause

    Time frame: From the date of assignment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 30 months

  2. Overall Survival (OS)

    OS is defined as the time from date of first dose of IMP until the date of death due to any cause. The analysis will include all dosed participants. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anticancer therapy

    Time frame: From the date of assignment until the date of death from any cause, assessed up to 30 months

  3. Disease control rate (DCR) at 12 weeks

    DCR at 12 weeks is defined as the percentage of participants who have at least 1 visit response of confirmed CR or PR or who have stable disease (SD) per RECIST 1.1 for at least 11 weeks as assessed by the investigator to all dosed participants

    Time frame: At 12 weeks after date of first dose

  4. Duration of Response (DoR)

    DoR is defined as the time from the date of first documented confirmed response until date of documented progression or death due to any cause. Analysis will include all dosed participants, with measurable disease at baseline who have a response, regardless of whether the participant withdraws from therapy, receives another anticancer treatment, or clinically progresses prior to PD.

    Time frame: From the date of first documented confirmed response until date of documented progression, assessed up to 30 months

  5. Time to Response (TTR)

    TTR is defined as the time from the start of the treatment to the first documented objective tumor response observed for participants who achieved CR or PR, as determined by the investigator according to RECIST 1.1. Analysis will include all dosed participants, with measurable disease at baseline who have a response, regardless of whether the participant withdraws from therapy, receives another anticancer treatment, or clinically progresses prior to PD.

    Time frame: From the date of first dose to the first documented objective tumor response, assessed up to 30 months

  6. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability].

    Treatment-emergent adverse events are defined as adverse events or worsening of pre-existing events with an onset date on or after first dose of IMP and within 90 (+ 7) days after last dose of study intervention or up to the day prior to start of subsequent therapy, whichever comes first.

    Time frame: From the time of ICF signature up to 30 months

07

Study locations

13 sites
  • Research Site
    Chelyabinsk, 454092, Russia
  • Research Site
    Krasnoyarsk, 660133, Russia
  • Research Site
    Kuzmolovskiy, 188663, Russia
  • Research Site
    Moscow, 111123, Russia
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Moscow, 115533, Russia
  • Research Site
    Moscow, 125284, Russia
  • Research Site
    Moscow, 142770, Russia
  • Research Site
    Moscow, 143423, Russia
  • Research Site
    Nizhny Novgorod, 603126, Russia
  • Research Site
    Saint Petersburg, 197022, Russia
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Volgograd, Unk, Russia
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.Yes,indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Aug 2026, 11 months.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's 11 months is below that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Aug 27, 2025
StartActual
Aug 29, 2025
Primary completionActual
Aug 14, 2026was Sep 2026
CompletionEst.
Sep 28, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 28, 2026→Aug 14, 2026 (actual)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Primary completion Sep 28, 2026→Aug 14, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07143604
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 27, 2025
Start date
Aug 29, 2025
Primary completion
Aug 14, 2026
Completion
Sep 28, 2027 (estimated)
Last update
Sep 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonesitatug vedotin

Start the discussion